Ectin Research
Hovås, Vastra Gotaland, Sweden
About Ectin Research
Some years ago a patient with spread and incurable bladder cancer was treated with a pharmaceutical against an unrelated tropical disease. This surprisingly resulted in that the cancer disease, as well as the metastasis, disappeared together with the tropical disease. Follow-up research suggests that a convenient oral combination therapy, MFA-370, consisting of the tropical medication and another well-established pharmaceutical, further enhance the anti-cancer effect in a wide range of cancer cell lines representing at least 40 % of all cancers. Today many cancer forms either lack treatment or the treatment is associated with severe side effects in the patients. Ectin Research, however, now offers a combination therapy MFA-370 consisting of two, highly utilized and with limited or no side effects, pharmaceuticals that will facilitate the developmental process to product. The aim of the company is to focus initially on treating metastasizing bladder cancer to prove the efficacy of the therapy, and to explore the treatment of other indications further on.
Company Facts
- Operating status: Closed
- Company type: For Profit
- IPO status: Private
- Employees: 11 – 50
- Estimated revenue: Less than $1M
- Total funding: $53.8K
- Last round: Grant (Feb 2017)
- Website: ectinresearch.com
- Phone: [email protected]
Industries & Categories
Medical, Pharmaceutical, Therapeutics
Social Profiles
Canonical: https://fsome.com/organization/ectin-research-2251354 · For the full interactive profile (charts, investors, team, acquisitions, press), please enable JavaScript.